[Pharmacokinetic monitoring as a new tool to individualize anti-TNF therapy]
- PMID: 24669890
[Pharmacokinetic monitoring as a new tool to individualize anti-TNF therapy]
Abstract
-
Comment in
-
[Individualized infliximab therapy: pharmacokinetic monitoring].Farm Hosp. 2015 Jan 1;39(1):59-60. doi: 10.7399/fh.2015.39.1.7791. Farm Hosp. 2015. PMID: 25680435 Spanish. No abstract available.
Similar articles
-
Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation.Curr Opin Oncol. 2000 Nov;12(6):582-7. doi: 10.1097/00001622-200011000-00011. Curr Opin Oncol. 2000. PMID: 11085458 Review.
-
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.Arthritis Rheum. 2006 Dec;54(12):3782-9. doi: 10.1002/art.22214. Arthritis Rheum. 2006. PMID: 17133559 Clinical Trial.
-
Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.Rheumatology (Oxford). 2007 May;46(5):736-41. doi: 10.1093/rheumatology/kem034. Epub 2007 Apr 2. Rheumatology (Oxford). 2007. PMID: 17403712 Review. No abstract available.
-
The New Test for Monitoring Infliximab Therapy: From Laboratory to Clinical Practice.Isr Med Assoc J. 2018 Feb;20(2):91-94. Isr Med Assoc J. 2018. PMID: 29431302
-
[TNF blocker infliximab receives award. Quality leap in therapy of chronic inflammatory diseases].MMW Fortschr Med. 2009 Nov 5;151(45):40-1. MMW Fortschr Med. 2009. PMID: 19960723 German. No abstract available.
Cited by
-
Observational Study to Compare Biological Drug Concentration Quantification Techniques and Immunogenicity in Patients with Immune-Mediated Diseases.Biomedicines. 2024 Apr 10;12(4):839. doi: 10.3390/biomedicines12040839. Biomedicines. 2024. PMID: 38672193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources